<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="173531">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836927</url>
  </required_header>
  <id_info>
    <org_study_id>8669-038</org_study_id>
    <secondary_id>AP23573-08-901</secondary_id>
    <nct_id>NCT00836927</nct_id>
  </id_info>
  <brief_title>Extension Trial of Deforolimus in Patients With Advanced Cancer (8669-038)</brief_title>
  <official_title>An Extension Trial of Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, for Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the long-term safety of deforolimus in patients for whom a clinical benefit has
      been established in a prior parent trial with deforolimus and/or in those who remain in
      long-term follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2009</start_date>
  <completion_date type="Anticipated">September 21, 2017</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of long-term deforolimus</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral or IV deforolimus, as described in the parent protocol. If the parent protocol involves a combination of deforolimus with one or several other drugs, the additional drug(s) may be continued as described in the parent protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ridaforolimus</intervention_name>
    <description>Oral or IV deforolimus, as described in the parent protocol. If the parent protocol involves a combination of deforolimus with one or several other drugs, the additional drug(s) may be continued as described in the parent protocol.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>deforolimus</other_name>
    <other_name>AP23573</other_name>
    <other_name>MK-8669</other_name>
    <other_name>ridaforolimus was also known as deforolimus until May 2009</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have participated on a deforolimus parent trial

          -  Patients must have derived a clinical benefit from the parent trial

          -  Patient is not on any other anti-cancer treatment(s) unless the therapy was allowed
             on the parent protocol

          -  ECOG performance status less than or equal to 2 if the patient is scheduled to
             receive treatment with deforolimus; no requirement if the patient is included for
             follow-up purposes only

          -  Patients of childbearing potential must have a negative pregnancy test within 7 days
             prior to screening and must use approved contraceptive from screening until 30 days
             after the last dose of study drug

          -  Signed informed consent

        Exclusion Criteria:

          -  Has not participated on a parent trial

          -  Women who are to receive study drug who are pregnant or lactating

          -  Any condition in the Investigator's judgment that renders the patient unable to fully
             understand and provide informed consent and/or comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>February 3, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
